CARLSBAD, Calif., Nov. 28, 2018 /PRNewswire/ -- Qualigen, Inc., a privately-owned company that provides novel diagnostic and therapeutic technologies for the treatment of cancer and infectious diseases, announced today the issuance of China Patent Number ZL 2017 30589986.5, which covers the design of Qualigen's novel FastPack 2.0 Sample Port. The patent, which provides protection until November 2027, is part of a family of patents and patent applications that protect Qualigen's FastPack "Laboratory in a Pouch" rapid immunoassay diagnostic technology. "We are pleased to strengthen our intellectual property protection with the addition of this new patent in China for our next-generation FastPack 2.0 System," stated Michael S. Poirier, Chief Executive Officer of Qualigen. "It is a key part of our continuing strategy to protect, improve and expand the utility of our FastPack and FastPack 2.0 diagnostic technologies in the U.S. and worldwide. To date, we have over 40 issued patents in this space."
About Qualigen, Inc.
Qualigen, Inc. is a medical device company focused on the development, production and commercialization of innovative medical technologies, including its flagship FastPack® point-of-care immunoassay system and novel therapeutic technologies for treatment of cancers and infectious diseases. For more information, visit www.qualigeninc.com.
SOURCE Qualigen, Inc.